Literature DB >> 29770849

Optimal method for measuring baseline metabolic tumor volume in DLBCL patients: are statistical agreements of SUV ≥2.5 satisfactory?

Eric Laffon1,2,3,4, Roger Marthan5,6,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29770849     DOI： 10.1007/s00259-018-4049-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  5 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

2.  On the Cutoff of Baseline Total Metabolic Tumor Volume in High-Tumor-Burden Follicular Lymphoma.

Authors:  Eric Laffon; Roger Marthan
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

3.  Reply to H.J.A. Adams et al and E. Laffon et al.

Authors:  Michel Meignan; Anne Ségolène Cottereau; Annibale Versari; Loïc Chartier; Jehan Dupuis; Sami Boussetta; Ilaria Grassi; René-Olivier Casasnovas; Corinne Haioun; Hervé Tilly; Vittoria Tarantino; Julien Dubreuil; Massimo Federico; Gilles Salles; Stefano Luminari; Judith Trotman
Journal:  J Clin Oncol       Date:  2016-12-28       Impact factor: 44.544

4.  All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting.

Authors:  Sally F Barrington; Tom Sulkin; Adam Forbes; Peter W M Johnson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-12-02       Impact factor: 9.236

5.  Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.

Authors:  Hajira Ilyas; N George Mikhaeel; Joel T Dunn; Fareen Rahman; Henrik Møller; Daniel Smith; Sally F Barrington
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-19       Impact factor: 9.236
  5 in total
  1 in total

1.  Could we avoid computing TMTV of DLBCL patients in routine practice?

Authors:  Eric Laffon; Roger Marthan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-07-28       Impact factor: 9.236
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.